Knowledge HQ

This is the published version of the study optimizing TIL propagation using K562 aAPCs. It confirms that the aAPC/G-Rex® platform supports rapid expansion of TILs to clinical scales with an effector-memory phenotype, comparable to PBMC feeders. Note: This is a duplicate study of 2014_Forgetet_al_TIL.pdf.

This study reports the expansion of HSPCs using Tat-MYC and Tat-Bcl-2 fusion proteins. G-Rex® 10 devices were used to expand CD34+ cells from cord blood, mobilized blood, and bone marrow. The expanded cells retained long-term repopulating activity and differentiated into multiple lineages in vivo.

This study defines optimized parameters for the G-Rex® 'M' series using K562 cells. It demonstrates that 1L of medium with optimal seeding allows 100-fold expansion in 10 days in the G-Rex® 100M. The platform showed linear scalability from 5 to 500 cm2 and validated glucose measurement for cell quantification.

This research investigates the kinetics of tumor destruction by CAR T cells targeting MUC1 and PSCA. G-Rex® 100M devices were used to expand the CAR-modified T cells. The study found that dual targeting improved efficacy but antigen intensity influenced killing; epigenetic modulation enhanced tumor susceptibility.

This conference paper reports a method for large-scale generation of myeloid dendritic cells (DCs) from cord blood CD34+ cells using G-Rex®10. The G-Rex® system yielded over 1.5 billion DCs, significantly outperforming conventional culture plates, and produced DCs capable of inducing Th1 responses.

This study demonstrates the generation of T-cell lines targeting WT1, Survivin, MAGE-A3, and PRAME from pediatric ALL patients using autologous DCs and PHA-blasts. The cells showed specific anti-leukemic activity. G-Rex® are referenced as a strategy for scaling up to clinical cell numbers.

This study utilized G-Rex® to expand NK cells from cord blood using artificial antigen presenting cells (aAPCs). The protocol achieved a mean 2389-fold expansion of high-purity NK cells in 14 days. Expanded cells demonstrated significant in vitro and in vivo cytotoxicity against multiple myeloma.

This study reports a simplified method to generate T cells targeting EBV, CMV, and Adenovirus using nucleofected dendritic cells and G-Rex® devices. The 10-day G-Rex® protocol produced clinically relevant cell numbers. Infused cells were safe and effective against active viral infections in HSCT recipients.

This study demonstrates that nicotinamide (NAM) enhances the homing and retention of NK cells in bone marrow, spleen, and lung. NK cells were expanded in G-Rex® devices under feeder-free conditions with IL-2 or IL-15. The G-Rex® platform supported large-scale expansion, yielding high-purity NK cells.

Compares unselected young TILs vs CD8+-enriched TILs. Mentions that G-Rex® were optimized for TIL therapy and introduced for clinical use. The study used (WAVE and G-Rex®) for high-density T-cell expansion, facilitating rapid accrual

Describes a protocol for expanding nTregs using G-Rex®10 and G-Rex®100 devices. The method yielded >10^9 Tregs in 21 days with high purity and suppressive function. G-Rex® promoted robust expansion (over 600-fold) compared to 24-well plates (5-6 fold) and maintained telomere length

Clinical trial results for TIL therapy in melanoma. Mentions using 'gas-permeable bags or GRex ' for the Rapid Expansion Procedure (REP). Notes that G-Rex® allow large-scale expansion to treatment levels (10^10 - 10^11 cells)